SEARCH:   Advanced

Blood, 15 September 2004, Vol. 104, No. 6, pp. 1898-1906. Prepublished online as a Blood First Edition Paper on June 1, 2004; DOI 10.1182/blood-2004-03-1010. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-03-1010v1 104/6/1898    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Baker, K. S. Articles by Bhatia, S. Search for Related Content PubMed PubMed Citation Articles by Baker, K. S. Articles by Bhatia, S. Related Collections Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study K. Scott Baker, James G. Gurney, Kirsten K. Ness, Ravi Bhatia, Stephen J. Forman, Liton Francisco, Philip B. McGlave, Leslie L. Robison, David S. Snyder, Daniel J. Weisdorf, and Smita Bhatia From the University of Minnesota Cancer Center, Blood and Marrow Transplant Program, and the Department of Pediatrics and the Department of Internal Medicine, University of Minnesota, Minneapolis, MN; and Hematology and Hematology/Bone Marrow Transplant, City of Hope Cancer Center, Duarte, CA. The purpose of this study was to analyze medical late effects among patients with chronic myeloid leukemia (CML) treated with hematopoietic cell transplantation (HCT). Subjects included 248 CML survivors who received an HC transplant (related donors [RDs], n = 150; unrelated donors [URDs], n = 70; or autologous, n = 28) and had survived at least 2 years, and a comparison group of 317 siblings. Subjects completed a 238-item survey on medical late effects. Compared with siblings, survivors were at a higher risk of developing ocular, oral health, endocrine, gastrointestinal, musculoskeletal, neurosensory, and neuromotor impairments. Multivariate analysis limited to RD and URD recipients found that chronic graft-versus-host disease (cGVHD) was associated with a higher risk of hypothyroidism, osteoporosis, cardiopulmonary, neurosensory, and neuromotor impairments. Overall health was reported as excellent, very good, or good in 78% of subjects, although those with cGVHD were more likely to report poor overall health. URD survivors were more likely to report a need for assistance with routine activities and that their current health prevented work or school attendance. This study demonstrates that HCT survivors, regardless of donor type, have a high prevalence of long-term health-related complications. However, adverse medical late effects with significant morbidity were uncommon. Chronic GVHD is the most important predictor of adverse medical late effects and poor overall health. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Wasilewski-Masker, S. C. Kaste, M. M. Hudson, N. Esiashvili, L. A. Mattano, and L. R. Meacham Bone Mineral Density Deficits in Survivors of Childhood Cancer: Long-term Follow-up Guidelines and Review of the Literature Pediatrics, March 1, 2008; 121(3): e705 - e713. [Abstract] [Full Text] [PDF] K. L. Syrjala, B. F. Kurland, J. R. Abrams, J. E. Sanders, and J. R. Heiman Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years Blood, February 1, 2008; 111(3): 989 - 996. [Abstract] [Full Text] [PDF] A. Cohen, A. Rovelli, D. F. Merlo, M. T. van Lint, E. Lanino, D. Bresters, M. Ceppi, V. Bocchini, A. Tichelli, and G. Socie Risk for Secondary Thyroid Carcinoma After Hematopoietic Stem-Cell Transplantation: An EBMT Late Effects Working Party Study J. Clin. Oncol., June 10, 2007; 25(17): 2449 - 2454. [Abstract] [Full Text] [PDF] Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease Blood, February 15, 2007; 109(4): 1756 - 1764. [Abstract] [Full Text] [PDF] C. J. Fraser, S. Bhatia, K. Ness, A. Carter, L. Francisco, M. Arora, P. Parker, S. Forman, D. Weisdorf, J. G. Gurney, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study Blood, October 15, 2006; 108(8): 2867 - 2873. [Abstract] [Full Text] [PDF] A. Quintas-Cardama and J. E. Cortes Chronic Myeloid Leukemia: Diagnosis and Treatment Mayo Clin. Proc., July 1, 2006; 81(7): 973 - 988. [Abstract] [Full Text] [PDF] A. Petryk, T. L. Bergemann, K. M. Polga, K. J. Ulrich, S. K. Raatz, D. M. Brown, L. L. Robison, and K. S. Baker Prospective Study of Changes in Bone Mineral Density and Turnover in Children after Hematopoietic Cell Transplantation J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 899 - 905. [Abstract] [Full Text] [PDF] K. L. Syrjala, S. L. Langer, J. R. Abrams, B. E. Storer, and P. J. Martin Late Effects of Hematopoietic Cell Transplantation Among 10-Year Adult Survivors Compared With Case-Matched Controls J. Clin. Oncol., September 20, 2005; 23(27): 6596 - 6606. [Abstract] [Full Text] [PDF] S. J. Lee New approaches for preventing and treating chronic graft-versus-host disease Blood, June 1, 2005; 105(11): 4200 - 4206. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020